|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
22.09.25 - 07:03
|
Global expansion of Idorsia′s QUVIVIQ continues as Simcere launches in China (GlobeNewswire EN)
|
|
|
Allschwil, Switzerland – September 22, 2025Idorsia Ltd. (SIX: IDIA) announces that Simcere Pharmaceuticals Group Ltd (2096.HK, “Simcere”) has launched QUVIVIQ® (daridorexant) in China. QUVIVIQ, Idorsia's dual orexin receptor antagonist, is indicated for the treatment of adult patients with insomnia characterized by difficulty falling asleep and/or maintaining sleep. Notably, QUVIVIQ has been approved without psychotropic drug control labeling, underscoring its differentiated clinical profile....
|
|
|
|
|
19.09.25 - 07:03
|
Idorsia′s JERAYGO (aprocitentan) approved in Switzerland for the treatment of resistant hypertension (GlobeNewswire EN)
|
|
|
Allschwil, Switzerland – September 19, 2025Idorsia Ltd (SIX: IDIA) announces that Swissmedic has granted marketing authorization for JERAYGO™ (aprocitentan) for the treatment of resistant hypertension in adult patients in combination with at least three antihypertensive medicinal products.1 The recommended dose is 12.5 mg orally once daily. The dose can be increased to 25 mg once daily for patients tolerating the 12.5 mg dose and in need of tighter blood pressure (BP) control.1...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
05.09.25 - 07:03
|
Idorsia to collaborate with two leading academic medical centers to launch IMPACT-HTN – a US initiative to transform care for patients with difficult-to-control hypertension (GlobeNewswire EN)
|
|
|
Allschwil, Switzerland & Radnor, Philadelphia – September 5, 2025Idorsia Ltd (SIX: IDIA) announces a first-of-its-kind initiative with the Stanford Hypertension Center and Duke Heart Center to launch IMPACT-HTN, a new three-phase program to transform and modernize the management of difficult-to-control hypertension. Patients requiring multiple medications for difficult-to-control hypertension face increasing challenges with care coordination, evaluation of underlying causes, and worsening outcomes. The initiative, led by Dr. Vivek Bhalla of the Stanford University School of Medicine and Dr. Sreekanth Vemulapalli of Duke University School of Medicine, is expected to generate real-world evidence, standardize clinical decision-making and deliver scalable tools that leverage AI technology to help identify patients with difficult-to-control hypertension who may benefit from innovative therapies that utilize new pathways, including Idorsia's once-daily TRYVIO™ (aprocitentan), the first systemic hypertensio...
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
